Peptides: overview

Bremelanotide cleared Phase 3 trials and earned an FDA label for premenopausal women with HSDD. The label is not indicated in men. What that means for the men driving most of the actual demand is an open, unanswered question.

Tesamorelin has the strongest regulatory file of any peptide in this space. The question is whether that approval proves what the longevity market thinks it proves.

Sermorelin's regulatory history is real. But the safety narrative built on top of it rests on a commercial withdrawal and a single cognition trial that may not have tested sermorelin at all.

BPC-157's rat data has held up for decades. Whether that mechanism does anything for the actual human joint you're injecting it into is a question a brand-new Phase 2 trial has only just started to answer.

KPV's rodent gut and inflammation data is genuinely coherent. Whether any of that biology survives contact with a human body has never been tested.

BPC-157, TB-500, and GHK-Cu are sold as one interchangeable injury-recovery stack, but their human evidence ranges from a real Phase 2 trial to a molecular identity gap to a null placebo-controlled result. Each is graded on its own record, not the group's pitch.

The Wolverine Stack pairs BPC-157 and TB-500 into one repair protocol — on paper a genuinely good idea: two peptides doing two different repair jobs. Here's what the pairing is meant to do for you, why the biology is exciting, and the one thing nobody has ever tested — the two of them run together.

BPC-157 is the repair peptide half the gym is talking about. Strip out the forum noise and the answer is simple: in animals it speeds healing by growing new blood supply into injured tissue. Here is what that could mean for you, how far the human proof goes, and what the FDA is about to review.

GHK-Cu is a copper-carrying peptide your body makes to repair itself, and makes less of as you age. Here's the plain-English answer: what it could do for you, why the biology is exciting, how far the human proof goes — and where the injectable form sits in the FDA's next compounding review.

You don't need a biology degree to judge peptide evidence yourself. You need five questions. Ask them of any study a seller quotes at you and the real signal pulls away from the sell — and the whole field gets more exciting once you can tell which promises have something under them.

MOTS-c and Epitalon are two very different longevity bets — one on your metabolism, one on the clock inside your cells. Here is what each could do for you, which angle fits your goal, and how far the human proof goes on both.

BPC-157's reputation rests on one mechanism — it appears to build fresh blood supply into damaged tissue. Here is that mechanism in plain language, angiogenesis and nitric oxide made simple, what it could mean for recovery, how far the animal proof goes, and the FDA review set for July 2026.

Peptides are the short chains of amino acids your body already uses to send signals — repair this, burn that, grow here. Some are drugs you trust, like insulin. Others are early and genuinely exciting. Here is the plain map of what they are, what they might do for you, and where the science stands.

Sermorelin and tesamorelin both nudge your pituitary to make more growth hormone. One targets deep visceral fat with a real Phase 3 behind it; the other is the gentler GH-axis nudge with an FDA past. Here's which one fits which goal — and why one is still an approved drug and the other isn't.

CJC-1295 and ipamorelin are the internet's favourite growth-hormone pairing — but they do two different jobs. One raises your GH baseline for days from a single shot; the other fires a clean nightly pulse. Here's what each could do for you, which fits which goal, and why so many people run both.

BPC-157 and TB-500 aren't two flavours of one recovery peptide — they're unrelated proteins aimed at different kinds of damage. Here is what each could actually do for you, which one fits which injury, and how far the human proof goes for both.

Selank is Russia's attempt at an anxiety peptide that takes the edge off without the sedation, the fog, or the dependence a benzodiazepine leaves you with. The early promise is real and genuinely interesting — here's what it could do for you, and how far the human proof actually goes.

Ipamorelin asks your own body to release a clean pulse of growth hormone — the recovery, sleep and body-composition signal — without the stress-hormone mess older compounds caused. Here's what that could mean for you, and how far the human proof actually goes.

CJC-1295 is engineered to make your own pituitary release growth hormone for days from a single shot — and unusually, a real human trial says it works. Here's what that could mean for recovery, sleep and body composition, how far the proof goes, and why one name hides two different compounds.

Sermorelin is the growth-hormone peptide with a real FDA past — and a clever way of working: it nudges your own gland to make more GH instead of overriding it. Here's what it could do for you, how far the human proof actually goes, and why its availability isn't waiting on the July FDA vote.

MOTS-c is a tiny peptide your mitochondria release when you train — a signal that tells your body to handle fuel and hold onto strength like a younger one. The early science is genuinely exciting. Here is what it could do for you, and how far the human proof actually goes.

DSIP (Emideltide on the FDA paperwork) is a peptide your body makes that peaks in your deepest sleep. The idea — hand it back to push deeper sleep and a steadier stress system — is genuinely interesting. Here is what it could do for you, and why the best human trial came back cold.

You've probably met ipamorelin as the second half of CJC-1295 and ipamorelin. On its own it's the quieter half — a small peptide built to ask your own body for a clean pulse of growth hormone. Here's what it could mean for you, why it earned the clean name, and how far the human proof goes.

MOTS-c is a tiny peptide your mitochondria make to help the body handle fuel and hold onto strength — and the level falls with age. Here's the plain-English tour: what it is, what the early science says it might do, and where the July 2026 FDA review just put it.

Semax is a Russian brain peptide with an unusual credential — three decades of real clinical use in stroke care, not just a biohacker rumour. Here is what it could do across neuroprotection and focus, how far the proof runs, and its spot on the FDA's July 2026 PCAC docket.